Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis

Objective. To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. Methods. Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Lib...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2020, Vol.2020 (2020), p.1-11
Main Authors: Dong, Shangjuan, Li, Niuniu, Wang, Liangmin, Ma, Jianling, Ji, Kun, Shi, Liqing
Format: Article
Language:English
Subjects:
Analysis
Chinese medicine
Clinical trials
Drug dosages
Fibrosis
Lung diseases
Medical prognosis
Medicine, Chinese
Meta-analysis
Pneumonia
Pulmonary fibrosis
Quality of life
Respiratory function
Respiratory tract diseases
Safety
Sensitivity analysis
Systematic review
Traditional Chinese medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c499t-2c11750b63a3db7ecf948b03c70d805b1f099de3559cdaeb71ef54a48dff3fa63
cites cdi_FETCH-LOGICAL-c499t-2c11750b63a3db7ecf948b03c70d805b1f099de3559cdaeb71ef54a48dff3fa63
container_end_page 11
container_issue 2020
container_start_page 1
container_title Evidence-based complementary and alternative medicine
container_volume 2020
creator Dong, Shangjuan
Li, Niuniu
Wang, Liangmin
Ma, Jianling
Ji, Kun
Shi, Liqing
description Objective. To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. Methods. Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. Results. A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p
doi_str_mv 10.1155/2020/1752387
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7040417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A622555825</galeid><sourcerecordid>A622555825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-2c11750b63a3db7ecf948b03c70d805b1f099de3559cdaeb71ef54a48dff3fa63</originalsourceid><addsrcrecordid>eNqNkc2LFDEQxYMo7ofePEvAi7C2m89Ox4MwDLu6sKLgCt5COqnsZOnpjJ1uZf570844q548pUh-eVWvHkLPKHlNqZTnjDByTpVkvFEP0DFVglaCNc3DQ62-HqGTnO8IYVop9RgdcUaJoI0-RnARQnTWbbHtPf5sA4xbnAK-GayPY0y97fByFXvIgD-Aj66UOPb4yse0seMqOvxp6taFG7b4MrZDyjG_wYsCj7ZalO_bcvEEPQq2y_B0f56iL5cXN8v31fXHd1fLxXXlhNZjxRwtRkhbc8t9q8AFLZqWcKeIb4hsaSBae-BSaucttIpCkMKKxofAg635KXq7091M7Rq8g34cbGc2Q1yX-Uyy0fz90seVuU3fjSKiLEQVgZd7gSF9myCPZh2zg66zPaQpG8bruuZSyRl98Q96l6ahGP5F0YZrIuU9dWs7MLEPqfR1s6hZ1IxJKRs2U692lCv7ywOEw8iUmDllM6ds9ikX_PmfNg_w71gLcLYDSnLe_oj_KQeFgWDvaSqFFoT_BOJEuKU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2361839055</pqid></control><display><type>article</type><title>Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Dong, Shangjuan ; Li, Niuniu ; Wang, Liangmin ; Ma, Jianling ; Ji, Kun ; Shi, Liqing</creator><contributor>Worsnop, Christopher ; Christopher Worsnop</contributor><creatorcontrib>Dong, Shangjuan ; Li, Niuniu ; Wang, Liangmin ; Ma, Jianling ; Ji, Kun ; Shi, Liqing ; Worsnop, Christopher ; Christopher Worsnop</creatorcontrib><description>Objective. To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. Methods. Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. Results. A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p&lt;0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p&lt;0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p&lt;0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p&lt;0.001) and other measurements and reduced SGRQ scores (SMD = −0.51, 95% CI −0.70 to −0.22, p&lt;0.001). Subgroup analysis of different study durations (3 months, ≥ 6 months) and comparison models (TCM vs. WM, TCM + WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27–1.60, p=0.352). There was no obvious publication bias, and the pooled results were stable according to sensitivity analysis. Conclusion. To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2020/1752387</identifier><identifier>PMID: 32104189</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Analysis ; Chinese medicine ; Clinical trials ; Drug dosages ; Fibrosis ; Lung diseases ; Medical prognosis ; Medicine, Chinese ; Meta-analysis ; Pneumonia ; Pulmonary fibrosis ; Quality of life ; Respiratory function ; Respiratory tract diseases ; Safety ; Sensitivity analysis ; Systematic review ; Traditional Chinese medicine</subject><ispartof>Evidence-based complementary and alternative medicine, 2020, Vol.2020 (2020), p.1-11</ispartof><rights>Copyright © 2020 Kun Ji et al.</rights><rights>COPYRIGHT 2020 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2020 Kun Ji et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Kun Ji et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-2c11750b63a3db7ecf948b03c70d805b1f099de3559cdaeb71ef54a48dff3fa63</citedby><cites>FETCH-LOGICAL-c499t-2c11750b63a3db7ecf948b03c70d805b1f099de3559cdaeb71ef54a48dff3fa63</cites><orcidid>0000-0003-0661-7637 ; 0000-0002-6808-4808 ; 0000-0001-7659-1677 ; 0000-0003-1928-5205 ; 0000-0001-5216-9324 ; 0000-0002-3701-7215</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2361839055/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2361839055?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,4009,25732,27902,27903,27904,36991,36992,44569,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32104189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Worsnop, Christopher</contributor><contributor>Christopher Worsnop</contributor><creatorcontrib>Dong, Shangjuan</creatorcontrib><creatorcontrib>Li, Niuniu</creatorcontrib><creatorcontrib>Wang, Liangmin</creatorcontrib><creatorcontrib>Ma, Jianling</creatorcontrib><creatorcontrib>Ji, Kun</creatorcontrib><creatorcontrib>Shi, Liqing</creatorcontrib><title>Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description>Objective. To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. Methods. Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. Results. A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p&lt;0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p&lt;0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p&lt;0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p&lt;0.001) and other measurements and reduced SGRQ scores (SMD = −0.51, 95% CI −0.70 to −0.22, p&lt;0.001). Subgroup analysis of different study durations (3 months, ≥ 6 months) and comparison models (TCM vs. WM, TCM + WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27–1.60, p=0.352). There was no obvious publication bias, and the pooled results were stable according to sensitivity analysis. Conclusion. To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future.</description><subject>Analysis</subject><subject>Chinese medicine</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>Fibrosis</subject><subject>Lung diseases</subject><subject>Medical prognosis</subject><subject>Medicine, Chinese</subject><subject>Meta-analysis</subject><subject>Pneumonia</subject><subject>Pulmonary fibrosis</subject><subject>Quality of life</subject><subject>Respiratory function</subject><subject>Respiratory tract diseases</subject><subject>Safety</subject><subject>Sensitivity analysis</subject><subject>Systematic review</subject><subject>Traditional Chinese medicine</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNkc2LFDEQxYMo7ofePEvAi7C2m89Ox4MwDLu6sKLgCt5COqnsZOnpjJ1uZf570844q548pUh-eVWvHkLPKHlNqZTnjDByTpVkvFEP0DFVglaCNc3DQ62-HqGTnO8IYVop9RgdcUaJoI0-RnARQnTWbbHtPf5sA4xbnAK-GayPY0y97fByFXvIgD-Aj66UOPb4yse0seMqOvxp6taFG7b4MrZDyjG_wYsCj7ZalO_bcvEEPQq2y_B0f56iL5cXN8v31fXHd1fLxXXlhNZjxRwtRkhbc8t9q8AFLZqWcKeIb4hsaSBae-BSaucttIpCkMKKxofAg635KXq7091M7Rq8g34cbGc2Q1yX-Uyy0fz90seVuU3fjSKiLEQVgZd7gSF9myCPZh2zg66zPaQpG8bruuZSyRl98Q96l6ahGP5F0YZrIuU9dWs7MLEPqfR1s6hZ1IxJKRs2U692lCv7ywOEw8iUmDllM6ds9ikX_PmfNg_w71gLcLYDSnLe_oj_KQeFgWDvaSqFFoT_BOJEuKU</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Dong, Shangjuan</creator><creator>Li, Niuniu</creator><creator>Wang, Liangmin</creator><creator>Ma, Jianling</creator><creator>Ji, Kun</creator><creator>Shi, Liqing</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0661-7637</orcidid><orcidid>https://orcid.org/0000-0002-6808-4808</orcidid><orcidid>https://orcid.org/0000-0001-7659-1677</orcidid><orcidid>https://orcid.org/0000-0003-1928-5205</orcidid><orcidid>https://orcid.org/0000-0001-5216-9324</orcidid><orcidid>https://orcid.org/0000-0002-3701-7215</orcidid></search><sort><creationdate>2020</creationdate><title>Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis</title><author>Dong, Shangjuan ; Li, Niuniu ; Wang, Liangmin ; Ma, Jianling ; Ji, Kun ; Shi, Liqing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-2c11750b63a3db7ecf948b03c70d805b1f099de3559cdaeb71ef54a48dff3fa63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analysis</topic><topic>Chinese medicine</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>Fibrosis</topic><topic>Lung diseases</topic><topic>Medical prognosis</topic><topic>Medicine, Chinese</topic><topic>Meta-analysis</topic><topic>Pneumonia</topic><topic>Pulmonary fibrosis</topic><topic>Quality of life</topic><topic>Respiratory function</topic><topic>Respiratory tract diseases</topic><topic>Safety</topic><topic>Sensitivity analysis</topic><topic>Systematic review</topic><topic>Traditional Chinese medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dong, Shangjuan</creatorcontrib><creatorcontrib>Li, Niuniu</creatorcontrib><creatorcontrib>Wang, Liangmin</creatorcontrib><creatorcontrib>Ma, Jianling</creatorcontrib><creatorcontrib>Ji, Kun</creatorcontrib><creatorcontrib>Shi, Liqing</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dong, Shangjuan</au><au>Li, Niuniu</au><au>Wang, Liangmin</au><au>Ma, Jianling</au><au>Ji, Kun</au><au>Shi, Liqing</au><au>Worsnop, Christopher</au><au>Christopher Worsnop</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Objective. To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. Methods. Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. Results. A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p&lt;0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p&lt;0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p&lt;0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p&lt;0.001) and other measurements and reduced SGRQ scores (SMD = −0.51, 95% CI −0.70 to −0.22, p&lt;0.001). Subgroup analysis of different study durations (3 months, ≥ 6 months) and comparison models (TCM vs. WM, TCM + WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27–1.60, p=0.352). There was no obvious publication bias, and the pooled results were stable according to sensitivity analysis. Conclusion. To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>32104189</pmid><doi>10.1155/2020/1752387</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0661-7637</orcidid><orcidid>https://orcid.org/0000-0002-6808-4808</orcidid><orcidid>https://orcid.org/0000-0001-7659-1677</orcidid><orcidid>https://orcid.org/0000-0003-1928-5205</orcidid><orcidid>https://orcid.org/0000-0001-5216-9324</orcidid><orcidid>https://orcid.org/0000-0002-3701-7215</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1741-427X
ispartof Evidence-based complementary and alternative medicine, 2020, Vol.2020 (2020), p.1-11
issn 1741-427X
1741-4288
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7040417
source Wiley Online Library Open Access; Publicly Available Content Database
subjects Analysis
Chinese medicine
Clinical trials
Drug dosages
Fibrosis
Lung diseases
Medical prognosis
Medicine, Chinese
Meta-analysis
Pneumonia
Pulmonary fibrosis
Quality of life
Respiratory function
Respiratory tract diseases
Safety
Sensitivity analysis
Systematic review
Traditional Chinese medicine
title Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A07%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Traditional%20Chinese%20Medicine%20in%20Idiopathic%20Pulmonary%20Fibrosis:%20A%20Meta-Analysis&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Dong,%20Shangjuan&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2020/1752387&rft_dat=%3Cgale_pubme%3EA622555825%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-2c11750b63a3db7ecf948b03c70d805b1f099de3559cdaeb71ef54a48dff3fa63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2361839055&rft_id=info:pmid/32104189&rft_galeid=A622555825&rfr_iscdi=true